Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2020 06:01 ET | Source: Immunocore Limited

Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020

PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3...
March 02, 2020 07:00 ET | Source: Immunocore Limited

Immunocore Secures $130 Million Series B Financing

Immunocore Secures $130 Million Series B Financing Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic ...
September 05, 2018 07:00 ET | Source: Immunocore Limited

Immunocore strengthens IP position in the field of TCR-based therapeutics

Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
September 05, 2018 02:00 ET | Source: Immunocore Limited

Immunocore strengthens IP position in the field of TCR-based therapeutics

PRESS RELEASE Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
August 20, 2018 07:00 ET | Source: Immunocore Limited

Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours

PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...
August 20, 2018 02:00 ET | Source: Immunocore Limited

Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours

PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...